After a string of promising late-stage results, Amgen’s cancer-fighting viral vaccine failed to extend patients’ lives at a statistically significant rate, missing a secondary endpoint and marking the first blemish on the biotech’s top cancer prospect.

…read more

Source: Amgen’s viral cancer vaccine misses its survival goal in melanoma PhIII


0 No comments